WeVote
Log In

Bill

Bill

S 7668

Prohibits the sale of xylazine above a certain weight

2025 Regular Session Introduced by Nathalia Fernández

Establishes a weight-based cap on xylazine sales, prohibiting deliveries above the threshold to curb large-quantity distribution and impact retailers, vets, and buyers.

COMMITTED TO RULES
0
WeVote Research Nonpartisan
Bill Summary · S 7668

Summary of Bill S 7668 — Prohibits the sale of xylazine above a certain weight

Overview and intent

S 7668 seeks to restrict the sale of xylazine by establishing a weight-based threshold, prohibiting the sale of the drug above that specified amount. The primary sponsor is Nathalia Fernandez. The bill appears to be designed to curb the distribution of larger quantities of xylazine, potentially addressing concerns about illicit use and public health risks associated with the drug.

Key provisions (based on available information)

  • Prohibition on sale: The core provision would prohibit selling xylazine above a defined weight threshold. The exact threshold is not provided in the available materials.
  • Threshold mechanism: While details are not specified in the provided text, the intended mechanism likely involves limiting bulk sales or requiring specific authorization for sales above the threshold.
  • Amendments: An amended version, S 7668A, was introduced on May 21, 2025, indicating revisions to the bill’s provisions (exact changes not enumerated in the materials provided).

Note: The precise definitions, enforcement provisions, penalties, licenses/registrations, reporting requirements, and effective dates are not included in the supplied materials. The summary reflects the bill’s stated objective and the fact that an amended version exists.

Who would be affected

  • Retailers, distributors, pharmacies, veterinary suppliers, and any entities that sell or distribute xylazine.
  • Potentially, purchasers who seek quantities above the threshold could face restrictions or additional compliance steps.
  • The bill may indirectly affect veterinary practices and clinics that utilize xylazine within regulatory limits.

Legislative history and status

  • Introduced: April 28, 2025
  • Referred to: Consumer Protection (April 28, 2025)
  • Amendments: S 7668A (amended version) introduced May 21, 2025
  • Key actions:
    • May 19-21, 2025: First and second committee/approval steps; advanced to third reading
    • May 21, 2025: Amended to 7668A and advanced
    • May 20, 2025: 2nd calendar report circulated
    • June 13, 2025: Committed to Rules (noted twice in the actions)
  • Current status: COMMITTED TO RULES

Related and companion legislation

  • Related Senate bills: S 6084 (prior-session)
  • Companion bills in the Assembly: A 1248 (listed as companion)

Practical implications and considerations

  • Public health and safety: Aims to reduce availability of larger quantities of xylazine, potentially addressing illicit distribution and associated harms.
  • Compliance and enforcement: Law would likely require businesses to verify quantities and manage sales to meet the threshold, potentially creating recordkeeping or reporting obligations and penalties for violations (details not specified in the materials).
  • Market impact: Could affect legitimate veterinary supply chains and access to xylazine for approved uses if thresholds are restrictive or enforcement is stringent.

For readers seeking specifics (the exact weight threshold, penalties, licensing requirements, and effective date), the bill text and any subsequent committee reports or fiscal notes should be consulted when they become available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.